Literature DB >> 18458774

Should cognitive impairment be included in the diagnostic criteria for schizophrenia?

Richard S E Keefe1.   

Abstract

Neurocognitive impairment is considered a core component of schizophrenia, and is increasingly under investigation as a potential treatment target. On average, cognitive impairment is severe to moderately severe compared to healthy controls, and almost all patients with schizophrenia demonstrate cognitive decrements compared to their expected level if they had not developed the illness. Compared to patients with affective disorders, cognitive impairment in schizophrenia appears earlier, is more severe, and is more independent of clinical symptoms. Although the DSM-IV-TR and ICD-10 descriptions of schizophrenia include several references to cognitive impairment, neither the diagnostic criteria nor the subtypology of schizophrenia include a requirement of cognitive impairment. This paper forwards for consideration a proposal that the diagnostic criteria include a specific criterion of "a level of cognitive functioning suggesting a consistent severe impairment and/or a significant decline from premorbid levels considering the patient's educational, familial, and socioeconomic background". The inclusion of this criterion may increase the "point of rarity" with affective psychoses and may increase clinicians' awareness of cognitive impairment, potentially leading to more accurate prognosis, better treatment outcomes, and a clearer diagnostic signal for genetic and biological studies. Future research will need to address the validity of these possibilities. The reliable determination of cognitive impairment as part of a standard diagnostic evaluation will present challenges to diagnosticians with limited resources or insufficient expertise. Cognitive assessment methods for clinicians, including brief assessments and interview-based assessments, are discussed. Given the current emphasis on the development of cognitive treatments, the evaluation of cognition in schizophrenia is an essential component of mental health education.

Entities:  

Keywords:  Schizophrenia; cognitive impairment; diagnosis; neurocognition

Year:  2008        PMID: 18458774      PMCID: PMC2327232          DOI: 10.1002/j.2051-5545.2008.tb00142.x

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  45 in total

1.  Defining a cognitive function decrement in schizophrenia.

Authors:  Richard S E Keefe; Charles E Eesley; Margaret P Poe
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

2.  A longitudinal study of neurocognitive function in individuals at-risk for psychosis.

Authors:  Richard S E Keefe; Diana O Perkins; Hongbin Gu; Robert B Zipursky; Bruce K Christensen; Jeffery A Lieberman
Journal:  Schizophr Res       Date:  2006-08-22       Impact factor: 4.939

3.  Baseline neurocognitive deficits in the CATIE schizophrenia trial.

Authors:  Richard S E Keefe; Robert M Bilder; Philip D Harvey; Sonia M Davis; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; Del D Miller; Jose M Canive; Lawrence W Adler; Theo C Manschreck; Marvin Swartz; Robert Rosenheck; Diana O Perkins; Trina M Walker; T Scott Stroup; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2006-04-19       Impact factor: 7.853

4.  Contrasts in neuropsychological test profile between patients with first-episode schizophrenia and first-episode affective disorders.

Authors:  M Albus; W Hubmann; C Wahlheim; N Sobizack; U Franz; F Mohr
Journal:  Acta Psychiatr Scand       Date:  1996-08       Impact factor: 6.392

Review 5.  Cognitive impairment as a target for pharmacological treatment in schizophrenia.

Authors:  M Davidson; R S Keefe
Journal:  Schizophr Res       Date:  1995-09       Impact factor: 4.939

Review 6.  Identification of separable cognitive factors in schizophrenia.

Authors:  Keith H Nuechterlein; Deanna M Barch; James M Gold; Terry E Goldberg; Michael F Green; Robert K Heaton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

7.  Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents.

Authors:  M Davidson; A Reichenberg; J Rabinowitz; M Weiser; Z Kaplan; M Mark
Journal:  Am J Psychiatry       Date:  1999-09       Impact factor: 18.112

8.  Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis.

Authors:  Warrick J Brewer; Shona M Francey; Stephen J Wood; Henry J Jackson; Christos Pantelis; Lisa J Phillips; Alison R Yung; Vicki A Anderson; Patrick D McGorry
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

Review 9.  How should DSM-V criteria for schizophrenia include cognitive impairment?

Authors:  Richard S E Keefe; Wayne S Fenton
Journal:  Schizophr Bull       Date:  2007-06-13       Impact factor: 9.306

10.  Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Authors:  Richard S E Keefe; John A Sweeney; Hongbin Gu; Robert M Hamer; Diana O Perkins; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

View more
  38 in total

1.  [Early dementia as primary syndrome of schizophrenia].

Authors:  F U Lang; R Klug; M Kunath; C Palm; I Uttner; M Jäger
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

2.  WPA contribution to the development of the chapter on mental disorders of the ICD-11.

Authors: 
Journal:  World Psychiatry       Date:  2012-06       Impact factor: 49.548

Review 3.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

4.  Autoimmune limbic encephalitis presenting as relapsing psychosis.

Authors:  Sarah A Hopkins; Kuven K Moodley; Dennis Chan
Journal:  BMJ Case Rep       Date:  2013-08-30

5.  WPA-WHO collaborative activities 2009-2011.

Authors:  Mario Maj
Journal:  World Psychiatry       Date:  2009-10       Impact factor: 49.548

6.  Anticipating DSM-V: opportunities and challenges for cognition and psychosis.

Authors:  Deanna M Barch; Richard S E Keefe
Journal:  Schizophr Bull       Date:  2009-11-18       Impact factor: 9.306

7.  Are psychiatrists an endangered species?

Authors:  Mario Maj
Journal:  World Psychiatry       Date:  2010-02       Impact factor: 49.548

8.  Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.

Authors:  Max Lam; W David Hill; Joey W Trampush; Jin Yu; Emma Knowles; Gail Davies; Eli Stahl; Laura Huckins; David C Liewald; Srdjan Djurovic; Ingrid Melle; Kjetil Sundet; Andrea Christoforou; Ivar Reinvang; Pamela DeRosse; Astri J Lundervold; Vidar M Steen; Thomas Espeseth; Katri Räikkönen; Elisabeth Widen; Aarno Palotie; Johan G Eriksson; Ina Giegling; Bettina Konte; Annette M Hartmann; Panos Roussos; Stella Giakoumaki; Katherine E Burdick; Antony Payton; William Ollier; Ornit Chiba-Falek; Deborah K Attix; Anna C Need; Elizabeth T Cirulli; Aristotle N Voineskos; Nikos C Stefanis; Dimitrios Avramopoulos; Alex Hatzimanolis; Dan E Arking; Nikolaos Smyrnis; Robert M Bilder; Nelson A Freimer; Tyrone D Cannon; Edythe London; Russell A Poldrack; Fred W Sabb; Eliza Congdon; Emily Drabant Conley; Matthew A Scult; Dwight Dickinson; Richard E Straub; Gary Donohoe; Derek Morris; Aiden Corvin; Michael Gill; Ahmad R Hariri; Daniel R Weinberger; Neil Pendleton; Panos Bitsios; Dan Rujescu; Jari Lahti; Stephanie Le Hellard; Matthew C Keller; Ole A Andreassen; Ian J Deary; David C Glahn; Anil K Malhotra; Todd Lencz
Journal:  Am J Hum Genet       Date:  2019-08-01       Impact factor: 11.025

9.  Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.

Authors:  Xiang Y Zhang; Da C Chen; Mei H Xiu; Fu D Yang; Yunlong Tan; Xingguang Luo; Lingjun Zuo; Therese A Kosten; Thomas R Kosten
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

Review 10.  Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond.

Authors:  Emre Bora; Murat Yücel; Christos Pantelis
Journal:  Schizophr Bull       Date:  2009-09-23       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.